July 24, 2016

The impact of asthma, chronic bronchitis and allergic rhinitis on all-cause hospitalizations and limitations in daily activities: a population-based observational study

  • Simone AccordiniEmail author,
  • Angelo Guido Corsico,
  • Lucia Calciano,
  • Roberto Bono,
  • Isa Cerveri,
  • Alessandro Fois,
  • Pietro Pirina,
  • Roberta Tassinari,
  • Giuseppe Verlato and
  • Roberto de Marco
Chronic respiratory diseases are a significant cause of morbidity and mortality worldwide. We sought to evaluate the impact of asthma, chronic bronchitis and allergic rhinitis on all-cause hospitalizations and limitations in daily activities in adults.

July 23, 2016

July 22, 2016

Drug allergy passport and other documentation for patients with drug hypersensitivity – An ENDA/EAACI Drug Allergy Interest Group Position Paper


  1. K. Brockow1,*
  2. W. Aberer2
  3. M. Atanaskovic-Markovic3
  4. S. Bavbek4
  5. A. Bircher5
  6. B. Bilo6
  7. M. Blanca7
  8. P. Bonadonna8
  9. G. Burbach9
  10. G. Calogiuri10
  11. C. Caruso11
  12. G. Celik12
  13. J. Cernadas13
  14. A Chiriac14
  15. P. Demoly14
  16. J.N.G. Oude Elberink15
  17. J. Fernandez16
  18. E. Gomes17
  19. L. H. Garvey18,
  20. J. Gooi19
  21. M. Gotua20
  22. M. Grosber1
  23. P. Kauppi21
  24. V. Kvedariene22
  25. J. J. Laguna23,
  26. J. Makoswska24
  27. H. Mosbech18
  28. A. Nakonechna25
  29. N. G. Papadopolous26
  30. J. Ring1
  31. A. Romano11,27
  32. H. Rockmann28,
  33. R. Sargur29
  34. L. Sedlackova30
  35. S. Sigurdardottir31
  36. B. Schnyder32
  37. T. Storaas33
  38. M. Torres7
  39. M. Zidarn34 and
  40. I. Terreehorst35
  41. Summary

    The strongest and best-documented risk factor for drug hypersensitivity (DH) is the history of a previous reaction. Accidental exposures to drugs to may lead to severe or even fatal reactions in sensitised patients. Preventable prescription errors are common. They are often due to inadequate medical history or poor risk assessment of recurrence of drug reaction. Proper documentation is essential information for the doctor to make sound therapeutic decision. The European Network on Drug Allergy and Drug Allergy Interest Group of the European Academy of Allergy and Clinical Immunology have formed a task force and developed a drug allergy passport as well as general guidelines of drug allergy documentation.

July 20, 2016

How Affiliation Disclosure and Control Over User-Generated Comments Affects Consumer Health Knowledge and Behavior

Journal of Medical Internet Research Published on 19.07.16 in Vol 18, No 7 (2016): July

Original Paper

Background: More people are seeking health information online than ever before and pharmaceutical companies are increasingly marketing their drugs through social media.
Objective: The aim was to examine two major concerns related to online direct-to-consumer pharmaceutical advertising: (1) how disclosing an affiliation with a pharmaceutical company affects how people respond to drug information produced by both health organizations and online commenters, and (2) how knowledge that health organizations control the display of user-generated comments affects consumer health knowledge and behavior.

Measuring the Role and Effectiveness of Online and Social Media in Increasing the Outreach of a Scientific Conference

Journal of Medical Internet Research Published on 19.07.16 in Vol 18, No 7 (2016): July

Original Paper

Background: Social media promotion is increasingly adopted by organizers of industry and academic events; however, the success of social media strategies is rarely questioned or the real impact scientifically analyzed.
Objective: We propose a framework that defines and analyses the impact, outreach, and effectiveness of social media for event promotion and research dissemination to participants of a scientific event as well as to the virtual audience through the Web.

Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study

Article in Press
Bilastine, a novel non-sedating second-generation H1 antihistamine, has been approved in most European countries since 2010. This study aimed to evaluate the superiority of bilastine over placebo in Japanese patients with perennial allergic rhinitis (PAR).

Allergists on Social Media